Pneumocystis infections: The iceberg?

Medical Mycology

Volumn 38, Issue , 2000, Pages 23-32

  Dei Cas, E ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Attachment mechanisms; Host defenses; Pneumocystis carinii; Surfactant

Indexed keywords

CD4 ANTIGEN; FREE RADICAL; INTERFERON; MANNOSE RECEPTOR; NITROGEN OXIDE; SURFACTANT; SURFACTANT ASSOCIATED PROTEIN;

CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; CONFERENCE PAPER; FUNGUS GROWTH; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; HYPERTROPHY; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; PATHOLOGY; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; T LYMPHOCYTE;

ANIMALS; CARRIER STATE; HUMANS; PNEUMOCYSTIS; PNEUMOCYSTIS INFECTIONS; PNEUMONIA, PNEUMOCYSTIS;

FUNGI; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII;

EID: 0034511762     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.23.32     Document Type: Article

References (125)

1. Update: Acquired immunodeficiency syndrome - United States
2. Pneumocystis carinii, un défi pour le biologiste
3. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated disorders and prior corticosteroid therapy
4. Pneumocystis carinii infection: Evidence for high prevalence in normal and immunosuppressed children
5. Serologic responses to Pneumocystis carinii antigens in health and disease
6. Infection with Pneumocystis carinii is prevalent in healthy Gambian children
7. Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii
8. Immunocompetent contacts of Pneumocystis carinii-infected-hosts can potentially transmit the disease to susceptible hosts
9. Pneumocystis carinii infection in patients with chronic bronchial disease
10. Natural mode of acquisition for de novo infection with Pneumocystis carinii
11. Introduction of Pneumocystis carinii in a colony of SCID mice
12. Transmission and epidemiology
13. Revised nomenclature for Pneumocystis carinii
14. Pneumocystis carinii is not universally transmissible between mammalian species
15. Intranasal inoculation of mouse, rat or rabbit-derived Pneumocystis in SCID mice
16. Pneumocystis cross infection experiments using SCID mice and Nude rats as recipient host, showed strong host-species specificity
17. Genetics, metabolism and host specificity of Pneumocystis carinii
18. Experimental models of Pneumocystis carinii infection
19. Multiplication of human-derived Pneumocystis carinii in severe combined immunodeficient (SCID) mice
20. Epidemiological and taxonomic impact of Pneumocystis biodiversity
21. Pneumocystis carinii: What is it, exactly?
22. Isoenzyme diversity in Pneumocystis carinii from rats, mice and rabbits
23. Pneumocystis carinii hominis sequencing to study hypothetical person-to-person transmission
24. Clusters of Pneumocystis carinii pneumonia: Analysis of person-to person transmission by genotyping
25. Severe pulmonary pneumocystosis in simian acquired immunodeficiency syndrome induced by simian immunodeficiency virus: Its characterization by polymerase-chain reaction method and failure of experimental transmission to immunodeficient animals
26. Maternal-fetal transmission of Pneumocystis carinii in human immunodeficiency virus infection
27. Pneumocystis in infants and children
28. Is Pneumocystis carinii vertically transmitted to neonatal rats?
29. Study on placental transmission of Pneumocystis carinii in mice using immunodeficient SCID mice as a new animal model
30. The young rabbit: A nonimmunosuppressed model for Pneumocystis carinii pneumonia
31. Animal models of pneumocystosis
32. In utero transmission of Pneumocystis carinii sp.f. oryctolagui
33. Pneumocystis carinii organisms from in vitro culture were highly infectious to the nude rat
34. European concerted action on Pneumocystis carinii. In vitro systems in Pneumocystis research
35. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora
36. Detection of Pneumocystis carinii DNA in air samples: Likely environmental risk to susceptible persons
37. Impaction versus filtration for the detection of Pneumocystis carinii DNA in air
38. Presence of Pneumocystis carinii DNA in pond water
39. Pneumocystis: The 'carrier state': Epidemiology and transmission of human pneumocystosis
40. Observations favouring Pneumocystis carinii pneumonia as a primary infection: A monoclonal antibody study on paraffin sections
41. A search for Pneumocystis carinii in post-mortem lungs by DNA amplification
42. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients
43. Pneumocystis carinii colonization in the absence of immunosuppression
44. Detection of Pneumocystis carinii among children with chronic respiratory disorders in the absence of HIV infection and immunodeficiency
45. Pneumocystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR
46. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: Assessing risk with blood CD4+ T cell counts
47. Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia
48. Latency is not an inevitable outcome of infection with Pneumocystis carinii
49. Serum titres of Pneumocystis carinii antibody in health care workers caring for patients with AIDS
50. DNA amplification in experimental pneumocystosis: Characterization of serum Pneumocystis carinii DNA and potential Pneumocystis carinii carrier states
51. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
52. Drug-resistant Pneumocystis carinii
53. Association of primary Pneumocystis carinii infection and sudden infant death syndrome
54. Pneumocystis carinii pneumonitis in young immunocompetent infants
55. Noninvasive methods for the diagnosis of pneumonia
56. Oropharyngeal samples for detection of Pneumocystis carinii by DNA amplification
57. Potential impact of Pneumocystis genetic diversity on the molecular detection of the parasite in human host
58. Oropharyngeal samples for genotyping and monitoring response to treatment in AIDS patients with Pneumocystis carinii pneumonia
59. Clinical manifestations in children
60. Pneumocystis pneumonia, an immunodeficiency-dependent disease: A critical historical overview
61. Pneumocystis and pneumocystosis in Europe at the end of the 20th century
62. Clinical manifestations in adults
63. Extrapulmonary pneumocystosis: The first 50 cases
64. Extrapulmonary Pneumocystis carinii infections in the acquired immunodeficiency syndrome
65. Extrapulmonary infection and other unusual manifestations of Pneumocystis carinii
66. Parasitic adaptation of pathogenic fungi to mammalian hosts
67. Does Pneumocystis carinii remain infectious in the bloodstream?
68. Search for extrapulmonary Pneumocystis carinii in an animal model
69. Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells
70. In vitro attachment of Pneumocystis carinii from mouse and rat origin
71. Gene for an extracellular matrix receptor protein from Pneumocystis carinii
72. Cell surface protease PRT1 identified in the fungal pathogen Pneumocystis carinii
73. Host-parasite relationships in Pneumocystis carinii infection: Activation of the plasmalemmal vesicular system in type I alveolar epithelial cells
74. Ultrastructural observations on the attachment of Pneumocystis carinii in vitro
75. Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia
76. Interaction of rat Pneumocystis carinii and rat alveolar epithelial cells in vitro
77. Pathogenic mechanisms
78. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia
79. Response to Pneumocystis infection in an immunocompetent host
80. Ultrastructural and molecular characterization of Pneumocystis carinii isolated from a rhesus monkey (Macaca mulatta)
81. Pneumocystis carinii infection in young non-immunosuppressed rabbits. Kinetics of infection and of primary specific immune response
82. Pneumocystis carinii: Oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage
83. Manganese-cofactored Superoxide Dismutase activity in rat-derived Pneumocystis carinii
84. Molecular cloning and characterization of a superoxide dismutase (sod) gene in Pneumocystis carinii
85. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4 but not CD8 T cells in severe combined immunodeficient mice
86. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon
87. The interaction Pneumocystis carinii with macrophages and L-cells
88. Alveolar macrophage interaction with Pneumocystis carinii
89. Uptake of Pneumocystis carinii mediated by macrophage mannose receptor
90. Pneumocystis carinii induces an oxidative burst in alveolar macrophages
91. Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model
92. Cultured rat and purified human Pneumocystis carinii stimulate intra- but not extracellular free radical production in human neutrophils
93. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonia in animal models
94. T cells are not sufficient for resistance to Pneumocystis carinii pneumonia in mice
95. Pneumocystosis pathophysiology
96. Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients
97. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia
98. Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients
99. Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease
100. Increased recovery of surfactant protein A in AIDS-related pneumonia
101. Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages
102. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice
103. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant
104. Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia
105. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia
106. Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat
107. Regulation of surfactant protein D expression by glucocorticoids in vitro and in vivo
108. Phospholipid composition of Pneumocystis carinii and effects of methylprednisolone immunosuppression on rat lung lipids
109. Surfactant changes during experimental pneumocystosis are related to the Pneumocystis development
110. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat
111. 120kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A
112. Surfactant protein D interacts with Pneumocystis carinii and mediates organisms adherence to alveolar macrophages
113. Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages
114. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats
115. Treatment of infection due to Pneumocystis carinii
116. Isoprenoid metabolism in Pneumocystis carinii
117. Treatment of Pneumocystis carinii with 1,3-glucan synthesis inhibitors
118. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat
119. Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi
120. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with atovaquone, pentamidine and trimethoprim/sulfamethoxazol against rat-derived Pneumocystis carinii
121. Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f.sp. hominis epidemiology
122. Pneumocystis carinii growth kinetics in culture systems and in hosts: Involvement of each life cycle parasite stage
123. Continuous axenic cultivation of Pneumocystis carinii